Table 2. Open in new tab Change in Days...

	Intercept Parameters (Indicative of Immediate Change)	Slope Parameters (Indicative of Long-Term Change)
Targeted antibiotics
Daptomycin	43.43	−9.47	−15.25 to −3.68	.002	0.43	−0.23	−.45 to −.02	.032
Linezolid	98.90	−6.94	−17.54 to 3.66	.197	1.32	−1.01	−1.40 to −.62	<.001
Meropenem	161.50	−43.49	−58.61 to −28.37	<.001	1.09	−1.39	−1.95 to −.83	<.001
Tigecycline	70.42	−35.47	−44.94 to −26.00	<.001	0.81	−0.67	−1.02 to −.33	<.001
Vancomycin	179.57	−7.38	−22.12 to 7.36	.323	−0.36	−0.18	−.72 to .36	.516
Nontargeted antibiotics
Cefepime	124.44	−2.32	−15.18 to 10.54	.721	−0.15	0.60	.13-1.08	.013
Ceftazidime	11.11	6.48	2.05 to 10.90	.005	0.12	0.01	−.15 to .17	.897
Piperacillin-tazobactam	126.66	32.51	18.74 to 46.27	<.001	−0.61	0.18	−.32 to .69	.477
Ertapenem	16.61	1.97	−.79 to 4.73	.160	0.27	−0.14	−.24 to −.04	.008

Intercept Parameters (Indicative of Immediate Change)

Slope Parameters (Indicative of Long-Term Change)

Antibiotic

Baseline Value

Calculated Change

95% CI

P Value

Baseline Value

Calculated Change

95% CI

P Value

Targeted antibiotics

Daptomycin

43.43

−9.47

−15.25 to −3.68

.002

0.43

−0.23

−.45 to −.02

.032

Linezolid

98.90

−6.94

−17.54 to 3.66

.197

1.32

−1.01

−1.40 to −.62

<.001

Meropenem

161.50

−43.49

−58.61 to −28.37

<.001

1.09

−1.39

−1.95 to −.83

<.001

Tigecycline

70.42

−35.47

−44.94 to −26.00

<.001

0.81

−0.67

−1.02 to −.33

<.001

Vancomycin

179.57

−7.38

−22.12 to 7.36

.323

−0.36

−0.18

−.72 to .36

.516

Nontargeted antibiotics

Cefepime

124.44

−2.32

−15.18 to 10.54

.721

−0.15

0.60

.13-1.08

.013

Ceftazidime

11.11

6.48

2.05 to 10.90

.005

0.12

0.01

−.15 to .17

.897

Piperacillin-tazobactam

126.66

32.51

18.74 to 46.27

<.001

−0.61

0.18

−.32 to .69

.477

Ertapenem

16.61

1.97

−.79 to 4.73

.160

0.27

−0.14

−.24 to −.04

.008

	Intercept Parameters (Indicative of Immediate Change)	Slope Parameters (Indicative of Long-Term Change)
Targeted antibiotics
Daptomycin	43.43	−9.47	−15.25 to −3.68	.002	0.43	−0.23	−.45 to −.02	.032
Linezolid	98.90	−6.94	−17.54 to 3.66	.197	1.32	−1.01	−1.40 to −.62	<.001
Meropenem	161.50	−43.49	−58.61 to −28.37	<.001	1.09	−1.39	−1.95 to −.83	<.001
Tigecycline	70.42	−35.47	−44.94 to −26.00	<.001	0.81	−0.67	−1.02 to −.33	<.001
Vancomycin	179.57	−7.38	−22.12 to 7.36	.323	−0.36	−0.18	−.72 to .36	.516
Nontargeted antibiotics
Cefepime	124.44	−2.32	−15.18 to 10.54	.721	−0.15	0.60	.13-1.08	.013
Ceftazidime	11.11	6.48	2.05 to 10.90	.005	0.12	0.01	−.15 to .17	.897
Piperacillin-tazobactam	126.66	32.51	18.74 to 46.27	<.001	−0.61	0.18	−.32 to .69	.477
Ertapenem	16.61	1.97	−.79 to 4.73	.160	0.27	−0.14	−.24 to −.04	.008

Table 2.

Open in new tab

Change in Days of Therapy per 1000 Patient Days (DOT/1000 PD) Following Implementation of Antibiotic Time-out

	Intercept Parameters (Indicative of Immediate Change)				Slope Parameters (Indicative of Long-Term Change)
Antibiotic	Baseline Value	Calculated Change	95% CI	P Value	Baseline Value	Calculated Change	95% CI	P Value
Targeted antibiotics
Daptomycin	43.43	−9.47	−15.25 to −3.68	.002	0.43	−0.23	−.45 to −.02	.032
Linezolid	98.90	−6.94	−17.54 to 3.66	.197	1.32	−1.01	−1.40 to −.62	<.001
Meropenem	161.50	−43.49	−58.61 to −28.37	<.001	1.09	−1.39	−1.95 to −.83	<.001
Tigecycline	70.42	−35.47	−44.94 to −26.00	<.001	0.81	−0.67	−1.02 to −.33	<.001
Vancomycin	179.57	−7.38	−22.12 to 7.36	.323	−0.36	−0.18	−.72 to .36	.516
Nontargeted antibiotics
Cefepime	124.44	−2.32	−15.18 to 10.54	.721	−0.15	0.60	.13-1.08	.013
Ceftazidime	11.11	6.48	2.05 to 10.90	.005	0.12	0.01	−.15 to .17	.897
Piperacillin-tazobactam	126.66	32.51	18.74 to 46.27	<.001	−0.61	0.18	−.32 to .69	.477
Ertapenem	16.61	1.97	−.79 to 4.73	.160	0.27	−0.14	−.24 to −.04	.008

	Intercept Parameters (Indicative of Immediate Change)				Slope Parameters (Indicative of Long-Term Change)
Antibiotic	Baseline Value	Calculated Change	95% CI	P Value	Baseline Value	Calculated Change	95% CI	P Value
Targeted antibiotics
Daptomycin	43.43	−9.47	−15.25 to −3.68	.002	0.43	−0.23	−.45 to −.02	.032
Linezolid	98.90	−6.94	−17.54 to 3.66	.197	1.32	−1.01	−1.40 to −.62	<.001
Meropenem	161.50	−43.49	−58.61 to −28.37	<.001	1.09	−1.39	−1.95 to −.83	<.001
Tigecycline	70.42	−35.47	−44.94 to −26.00	<.001	0.81	−0.67	−1.02 to −.33	<.001
Vancomycin	179.57	−7.38	−22.12 to 7.36	.323	−0.36	−0.18	−.72 to .36	.516
Nontargeted antibiotics
Cefepime	124.44	−2.32	−15.18 to 10.54	.721	−0.15	0.60	.13-1.08	.013
Ceftazidime	11.11	6.48	2.05 to 10.90	.005	0.12	0.01	−.15 to .17	.897
Piperacillin-tazobactam	126.66	32.51	18.74 to 46.27	<.001	−0.61	0.18	−.32 to .69	.477
Ertapenem	16.61	1.97	−.79 to 4.73	.160	0.27	−0.14	−.24 to −.04	.008

All values correspond to a linear combination of parameter estimates for the pre- and post- values of the segmented regression analysis.

Abbreviations: CI, confidence interval; DOT/1000 PD, days of therapy per 1000 patient-days.

This Feature Is Available To Subscribers Only